Epidemiology of EML4-ALK translocations in a small, German non-small-cell lung cancer patient cohort

Personalized Medicine

Volumn 9, Issue 8, 2012, Pages 801-803

  Schildgen, Verena ^a   Lochi, Vincenza ^a   Lüsebrink, Jessica ^a   Brockmann, Michael ^a   Schildgen, Oliver ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

ALK; cancer; EML4; lung; NSCLC; translocation

Indexed keywords

EML4 ALK PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; COHORT ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL;

EID: 84869791982     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.12.94     Document Type: Article

References (8)

1. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin. Cancer Res. 17(8), 2081-2086 (2011).
2. Just PA, Cazes A, Audebourg A et al. Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: A comprehensive study of Caucasian non-smokers. Lung Cancer 76(3), 309-315 (2012).
3. Galetta D, Rossi A, Pisconti S, Colucci G. The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Ther. Targets 16(Suppl. 2), S45-S54 (2012).
4. Horn L, Pao W. EML4-ALK: Honing in on a new target in non-small-cell lung cancer. J. Clin. Oncol. 27(26), 4232-4235 (2009).
5. Togashi Y, Soda M, Sakata S et al. KLC1-ALK: A novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS ONE 7(2), e31323 (2012).
6. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363(18), 1693-1703 (2010).
7. Butrynski JE, D'Adamo DR, Hornick JL et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363(18), 1727-1733 (2010).
8. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27(26), 4247-4253 (2009